{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T10:59:21Z","timestamp":1781521161467,"version":"3.54.1"},"reference-count":48,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2018,11,26]],"date-time":"2018-11-26T00:00:00Z","timestamp":1543190400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,11,1]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The search of personalized treatment for a subject with immunoglobulin A nephropathy (IgAN) is appealing since the individual long-term outcome is highly variable in spite of common mild clinical signs such as microscopic haematuria, moderate proteinuria and slightly reduced glomerular filtration rate (GFR). The only risk factor considered by the Kidney Disease: Improving Global Outcomes (KDIGO) guidelines to target corticosteroid\/immunosuppressive treatment in IgAN is proteinuria persistently &gt;1\u2009g\/day despite 3\u20136\u2009months of optimized supportive care. However, proteinuria in IgAN may result not only from active lesions but also from sclerotic glomerular lesions with hyperfiltration and tubular damage. The Oxford classification study and subsequent investigations have indicated the value of pathology risk factors for progression independent of proteinuria, blood pressure and GFR at renal biopsy. Meanwhile new studies have provided an improved understanding of the pathogenetic mechanisms operating in IgAN leading to kidney tissue damage. These findings suggest the possibility for the individual patient with IgAN of using a pathology-based therapy, taking into consideration the pathogenetic mechanisms operating at the time of renal biopsy. This review is largely opinion based, since evidence-based reports are mostly incomplete: hypotheses are suggested based on interesting published investigations. The clinician faces a daily challenge: find the best management for his\/her patient, modelling a rather general indication as obtained by the guidelines to the needs of the patient. This review offers some considerations that hopefully will be useful in this difficult choice.<\/jats:p>","DOI":"10.1093\/ndt\/gfy338","type":"journal-article","created":{"date-parts":[[2018,10,8]],"date-time":"2018-10-08T11:08:45Z","timestamp":1538996925000},"page":"1832-1838","source":"Crossref","is-referenced-by-count":22,"title":["Towards a personalized treatment for IgA nephropathy considering pathology and pathogenesis"],"prefix":"10.1093","volume":"34","author":[{"given":"Rosanna","family":"Coppo","sequence":"first","affiliation":[{"name":"Fondazione Ricerca Molinette, Regina Margherita Hospital, Turin, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2018,11,26]]},"reference":[{"key":"2019110402560240100_gfy338-B1","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1007\/s40620-016-0360-z","article-title":"Clinical and histological risk factors for progression of IgA nephropathy: an update in children, young and adult patients","volume":"30","author":"Coppo","year":"2017","journal-title":"J Nephrol"},{"key":"2019110402560240100_gfy338-B2","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1097\/MNH.0000000000000405","article-title":"An update on predicting renal progression in IgA nephropathy","volume":"27","author":"Barbour","year":"2018","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2019110402560240100_gfy338-B3","first-page":"139","article-title":"KDIGO clinical practice guideline for glomerulonephritis","volume":"2","year":"2012","journal-title":"Kidney Int"},{"key":"2019110402560240100_gfy338-B4","doi-asserted-by":"crossref","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","article-title":"STOP-IgAN investigators: intensive supportive care plus immunosuppression in IgA nephropathy","volume":"373","author":"Rauen","year":"2015","journal-title":"N Engl J Med"},{"key":"2019110402560240100_gfy338-B5","doi-asserted-by":"crossref","first-page":"432","DOI":"10.1001\/jama.2017.9362","article-title":"Effect of oral methylprednisolone on clinical outcomes in patients with IgA nephropathy: the TESTING randomized clinical trial","volume":"318","author":"Lv","year":"2017","journal-title":"JAMA"},{"key":"2019110402560240100_gfy338-B6","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1681\/ASN.2016060640","article-title":"A randomized, controlled trial of rituximab in IgA nephropathy with proteinuria and renal dysfunction","volume":"28","author":"Lafayette","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2019110402560240100_gfy338-B7","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","article-title":"Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): a double-blind, randomised, placebo-controlled phase 2b trial","volume":"389","author":"Fellstr\u00f6m","year":"2017","journal-title":"Lancet"},{"key":"2019110402560240100_gfy338-B8","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s00467-017-3699-z","article-title":"New insights into the pathogenesis of IgA nephropathy","volume":"33","author":"Yeo","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"2019110402560240100_gfy338-B9","doi-asserted-by":"crossref","first-page":"1795","DOI":"10.1681\/ASN.2011050464","article-title":"The pathophysiology of IgA nephropathy","volume":"22","author":"Suzuki","year":"2011","journal-title":"J Am Soc Nephrol"},{"key":"2019110402560240100_gfy338-B10","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1038\/ki.2009.168","article-title":"The Oxford classification of IgA nephropathy: pathology definitions, correlations, and reproducibility","volume":"76","author":"Roberts","year":"2009","journal-title":"Kidney Int"},{"key":"2019110402560240100_gfy338-B11","doi-asserted-by":"crossref","first-page":"534","DOI":"10.1038\/ki.2009.243","article-title":"The Oxford classification of IgA nephropathy: rationale, clinicopathological correlations, and classification","volume":"76","author":"Cattran","year":"2009","journal-title":"Kidney Int"},{"key":"2019110402560240100_gfy338-B12","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1038\/ki.2010.43","article-title":"The Oxford IgA nephropathy clinicopathological classification is valid for children as well as adults","volume":"77","author":"Coppo","year":"2010","journal-title":"Kidney Int"},{"key":"2019110402560240100_gfy338-B13","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1681\/ASN.2016040433","article-title":"A multicenter study of the predictive value of crescents in IgA nephropathy","volume":"28","author":"Haas","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2019110402560240100_gfy338-B14","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","article-title":"Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy Classification Working Group","volume":"91","author":"Trimarchi","year":"2017","journal-title":"Kidney Int"},{"key":"2019110402560240100_gfy338-B15","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1038\/ki.2014.63","article-title":"Validation of the Oxford classification of IgA nephropathy in cohorts with different presentations and treatments","volume":"86","author":"Coppo","year":"2014","journal-title":"Kidney Int"},{"key":"2019110402560240100_gfy338-B16","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1681\/ASN.2014070697","article-title":"Corticosteroids in IgA nephropathy: a retrospective analysis from the VALIGA study","volume":"26","author":"Tesar","year":"2015","journal-title":"J Am Soc Nephrol"},{"key":"2019110402560240100_gfy338-B17","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfy302","article-title":"Is there long-term value of pathology scoring in IgA nephropathy? A VALIGA update","author":"Coppo","year":"2018","journal-title":"Nephrol Dial Transplant"},{"key":"2019110402560240100_gfy338-B18","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s00467-016-3469-3","article-title":"Risk factors for progression in children and young adults with IgA nephropathy: an analysis of 261 cases from the VALIGA European cohort","volume":"32","author":"Coppo","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"2019110402560240100_gfy338-B19","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1038\/ki.2015.322","article-title":"The MEST score provides earlier risk prediction in IgA nephropathy","volume":"89","author":"Barbour","year":"2016","journal-title":"Kidney Int"},{"key":"2019110402560240100_gfy338-B20","doi-asserted-by":"crossref","first-page":"511","DOI":"10.2215\/CJN.01120905","article-title":"Steroid treatment for severe childhood IgA nephropathy: a randomized, controlled trial","volume":"1","author":"Yoshikawa","year":"2006","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019110402560240100_gfy338-B21","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.2215\/CJN.08630910","article-title":"Long-term results of a randomized controlled trial in childhood IgA nephropathy","volume":"6","author":"Kamei","year":"2011","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019110402560240100_gfy338-B22","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1053\/ajkd.2002.31399","article-title":"Regression of IgA nephropathy: a repeat biopsy study","volume":"39","author":"Hotta","year":"2002","journal-title":"Am J Kidney Dis"},{"key":"2019110402560240100_gfy338-B23","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.kint.2016.09.029","article-title":"Evidence from the Oxford classification cohort supports the clinical value of subclassification of focal segmental glomerulosclerosis in IgA nephropathy","volume":"91","author":"Bellur","year":"2017","journal-title":"Kidney Int"},{"key":"2019110402560240100_gfy338-B24","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1007\/s40620-015-0227-8","article-title":"Prognostic value of endocapillary hypercellularity in IgA nephropathy patients with no immunosuppression","volume":"29","author":"Chakera","year":"2016","journal-title":"J Nephrol"},{"key":"2019110402560240100_gfy338-B25","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1097\/MNH.0000000000000312","article-title":"IgA nephropathy: an update","volume":"26","author":"Soares","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2019110402560240100_gfy338-B26","doi-asserted-by":"crossref","first-page":"i123","DOI":"10.1093\/ndt\/gfw326","article-title":"Mycophenolate mofetil therapy in immunoglobulin A nephropathy: histological changes after treatment","volume":"32","author":"Beckwith","year":"2017","journal-title":"Nephrol Dial Transplant"},{"key":"2019110402560240100_gfy338-B27","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1053\/j.ajkd.2016.11.027","article-title":"Mycophenolate mofetil combined with prednisone versus full-dose prednisone in IgA nephropathy with active proliferative lesions: a randomized controlled trial","volume":"69","author":"Hou","year":"2017","journal-title":"Am J Kidney Dis"},{"key":"2019110402560240100_gfy338-B28","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40620-014-0165-x","article-title":"Reversal of active glomerular lesions after immunosuppressive therapy in patients with IgA nephropathy: a repeat-biopsy based observation","volume":"28","author":"Shen","year":"2015","journal-title":"J Nephrol"},{"key":"2019110402560240100_gfy338-B29","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1097\/MNH.0b013e32835fe65c","article-title":"Oxford classification of immunoglobulin A nephropathy: an update","volume":"22","author":"Roberts","year":"2013","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2019110402560240100_gfy338-B30","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1038\/s41598-017-01223-3","article-title":"Tubular atrophy\/interstitial fibrosis scores of Oxford classification combined with proteinuria level at biopsy provides earlier risk prediction in IgA nephropathy","volume":"7","author":"Zhu","year":"2017","journal-title":"Sci Rep"},{"key":"2019110402560240100_gfy338-B31","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1681\/ASN.V131142","article-title":"Controlled prospective trial of prednisolone and cytotoxics in progressive IgA nephropathy","volume":"13","author":"Ballardie","year":"2002","journal-title":"J Am Soc Nephrol"},{"key":"2019110402560240100_gfy338-B32","doi-asserted-by":"crossref","first-page":"1321","DOI":"10.1093\/ndt\/gfg081","article-title":"Crescentic, proliferative IgA nephropathy: clinical and histological response to methylprednisolone and intravenous cyclophosphamide","volume":"18","author":"Tumlin","year":"2003","journal-title":"Nephrol Dial Transplant"},{"key":"2019110402560240100_gfy338-B33","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1111\/cei.12823","article-title":"Why, when and how should immunosuppressive therapy considered in patients with immunoglobulin A nephropathy?","volume":"186","author":"Rasche","year":"2016","journal-title":"Clin Exp Immunol"},{"key":"2019110402560240100_gfy338-B34","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1681\/ASN.2016060647","article-title":"Corticosteroids in IgA nephropathy: lessons from recent studies","volume":"28","author":"Coppo","year":"2017","journal-title":"J Am Soc Nephrol"},{"key":"2019110402560240100_gfy338-B35","doi-asserted-by":"crossref","first-page":"973","DOI":"10.2215\/CJN.02300215","article-title":"Changes in proteinuria and side effects of corticosteroids alone or in combination with azathioprine at different stages of IgA nephropathy","volume":"11","author":"Sarcina","year":"2016","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019110402560240100_gfy338-B36","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/s00467-017-3652-1","article-title":"The gut-kidney axis in IgA nephropathy: role of microbiota and diet on genetic predisposition","volume":"33","author":"Coppo","year":"2018","journal-title":"Pediatr Nephrol"},{"key":"2019110402560240100_gfy338-B37","doi-asserted-by":"crossref","first-page":"S1","DOI":"10.1016\/j.nephro.2018.02.004","article-title":"Recent advances in the physiopathology of IgA nephropathy","volume":"14(Suppl 1)","author":"Monteiro","year":"2018","journal-title":"Nephrol Ther"},{"key":"2019110402560240100_gfy338-B38","doi-asserted-by":"crossref","first-page":"3991","DOI":"10.1172\/JCI45563","article-title":"Mice overexpressing BAFF develop a commensal flora-dependent, IgA-associated nephropathy","volume":"121","author":"McCarthy","year":"2011","journal-title":"J Clin Invest"},{"key":"2019110402560240100_gfy338-B39","doi-asserted-by":"crossref","first-page":"276","DOI":"10.1038\/ki.2015.94","article-title":"Gluten exacerbates IgA nephropathy in humanized mice through gliadin-CD89 interaction","volume":"88","author":"Papista","year":"2015","journal-title":"Kidney Int"},{"key":"2019110402560240100_gfy338-B40","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1007\/s00467-016-3390-9","article-title":"Biomarkers and targeted new therapies for IgA nephropathy","volume":"32","author":"Coppo","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"2019110402560240100_gfy338-B41","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.kint.2018.02.023","article-title":"Circulating complement factor H-related protein 5 levels contribute to development and progression of IgA nephropathy","volume":"94","author":"Zhu","year":"2018","journal-title":"Kidney Int"},{"key":"2019110402560240100_gfy338-B42","doi-asserted-by":"crossref","DOI":"10.1093\/ndt\/gfy064","article-title":"Defective gene expression of the membrane complement inhibitor CD46 in patients with progressive immunoglobulin A nephropathy","author":"Coppo","year":"2019","journal-title":"Nephrol Dial Transplant"},{"key":"2019110402560240100_gfy338-B43","doi-asserted-by":"crossref","first-page":"897","DOI":"10.2215\/CJN.09710913","article-title":"Association of C4d deposition with clinical outcomes in IgA nephropathy","volume":"9","author":"Espinosa","year":"2014","journal-title":"Clin J Am Soc Nephrol"},{"key":"2019110402560240100_gfy338-B44","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1007\/s00467-016-3575-2","article-title":"C4d deposits in IgA nephropathy: where does complement activation come from?","volume":"32","author":"Coppo","year":"2017","journal-title":"Pediatr Nephrol"},{"key":"2019110402560240100_gfy338-B45","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1093\/ckj\/sfv076","article-title":"Use of eculizumab in crescentic IgA nephropathy: proof of principle and conundrum?","volume":"8","author":"Ring","year":"2015","journal-title":"Clin Kidney J"},{"key":"2019110402560240100_gfy338-B46","first-page":"123","article-title":"Breaking down the complement system: a review and update on novel therapies","volume":"26","author":"Reddy","year":"2017","journal-title":"Curr Opin Nephrol Hypertens"},{"key":"2019110402560240100_gfy338-B47","doi-asserted-by":"crossref","first-page":"1356","DOI":"10.1016\/j.kint.2018.01.005","article-title":"Interleukin-6 is essential for glomerular immunoglobulin A deposition and the development of renal pathology in Cd37-deficient mice","volume":"93","author":"Rops","year":"2018","journal-title":"Kidney Int"},{"key":"2019110402560240100_gfy338-B48","doi-asserted-by":"crossref","first-page":"1194","DOI":"10.1016\/j.ekir.2017.07.002","article-title":"Inhibition of STAT3 signaling reduces IgA1 autoantigen production in IgA nephropathy","volume":"2","author":"Yamada","year":"2017","journal-title":"Kidney Int Rep"}],"container-title":["Nephrology Dialysis Transplantation"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/11\/1832\/30335719\/gfy338.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/academic.oup.com\/ndt\/article-pdf\/34\/11\/1832\/30335719\/gfy338.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,3]],"date-time":"2022-09-03T15:41:40Z","timestamp":1662219700000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ndt\/article\/34\/11\/1832\/5210033"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,11,26]]},"references-count":48,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2018,11,26]]},"published-print":{"date-parts":[[2019,11,1]]}},"URL":"https:\/\/doi.org\/10.1093\/ndt\/gfy338","relation":{},"ISSN":["0931-0509","1460-2385"],"issn-type":[{"value":"0931-0509","type":"print"},{"value":"1460-2385","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2019,11]]},"published":{"date-parts":[[2018,11,26]]}}}